Skip to main content

Table 5 Diagnostic power of IL6 to discriminate patients with HCC from patients with cirrhosis in different three staging systems

From: A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus

Classification AUC Sens% Spe% PPV% NPV% AC%
Number of nodules (n, %)
 Single (67, 43.2%) 0.82 78 70 44 91 72
 Multiple (88, 56.8) 0.82 78 70 67 81 74
Macrovascular invasion (n, %)
 Absent (141, 91%) 0.81 77 70 67 78 73
 Present (14, 9%) 0.85 83 70 36 96 72
Size of nodules (n, %)
 <2 (48, 31%) 0.82 78 70 44 91 72
 >2 (107, 69%) 0.82 78 70 67 81 74
BCLC stage (n, %)
 0-A (109, 70.3%) 0.77 71 70 63 78 71
 B (46, 29.7) 0.91 91 70 53 96 76
CLIP stage (n, %)
 0-1 (122, 79%) 0.78 75 70 67 78 72
 2-3 (33, 21%) 0.95 88 70 44 96 74
Okuda stage (n, %)
 Stage I (117, 75.5%) 0.79 77 70 65 81 73
 Stage II (38, 24.5%) 0.88 80 70 47 85 73